Decomposition Analysis of Spending and Price Trends for  Biologic Anti‐Rheumatic Drugs in Medicare and Medicaid

ConclusionPost ‐market drug‐price changes alone account for the majority of recent spending growth for bDMARDs. Policy interventions targeting price increases, particularly under Part D plans, may help mitigate drug financial burdens for public payers and bDMARD recipients.

Source: Arthritis and Rheumatology - October 13, 2019 Category: Rheumatology Authors: Natalie McCormick, Zachary S. Wallace, Chana A. Sacks, John Hsu, Hyon K. Choi Tags: FULL LENGTH Source Type: research